Eli Lilly Stocks $1.5B Orforglipron Inventory, Advances Gene Therapy Combo
Under collaboration with CRISPR Therapeutics, Eli Lilly is evaluating zugo-cel in combination with its BTK inhibitor pirtobrutinib for systemic lupus erythematosus and B-cell malignancies. The company has built a $1.5 billion inventory of orforglipron pills ahead of an upcoming FDA review to ensure immediate post-approval supply.
1. Gene Therapy Collaboration
Under collaboration with CRISPR Therapeutics, Eli Lilly is evaluating zugo-cel in combination with its BTK inhibitor pirtobrutinib in early-stage studies targeting systemic lupus erythematosus and B-cell malignancies. This partnership leverages Lilly’s oncology expertise and CRISPR’s gene-editing platform to explore potential synergistic benefits in autoimmune and hematologic cancers.
2. Orforglipron Inventory Build-Up
Eli Lilly has assembled a $1.5 billion stockpile of its oral obesity therapy, orforglipron, ahead of a pending FDA decision. This strategic build ensures uninterrupted supply and rapid patient access upon potential approval, mitigating risks of launch delays or shortages.